Focus: Corcept Therapeutics is a mid-cap biotech company focused on small-molecule therapeutics across oncology, endocrinology, infectious diseases, neurology, and gastroenterology. The company is primarily revenue-driven by its marketed product KORLYM, generating ~$229M in annual Part D spending.
Profile data last refreshed 10h ago · AI intelligence enriched 2w ago
Stable — net +2 jobs in 30d
24 added, 22 removed. Backfill posture.
Corcept offers stable, commercially-driven roles with strong near-term revenue visibility, but career growth depends heavily on pipeline Phase 3 success and tolerance for a single-product risk profile.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Lead revenue driver representing 100% of company revenue; patent protection extends to 2038, providing >10 years of market exclusivity.
Help build intelligence for Corcept Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Corcept Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Generic mifepristone formulation in post-LOE phase; represents competitive pressure and generic erosion of branded product value.
Additional generic mifepristone formulation in post-LOE phase; compounds generic competitive pressure on branded portfolio.
Branded mifepristone product approaching loss of exclusivity; faces imminent generic competition and revenue erosion.
Corcept Therapeutics shares surge 22% after Q2 beat, guidance raise - scanx.trade
Corcept Therapeutics shares surge 22% after Q2 beat, guidance raise scanx.trade
Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know - Benzinga
Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know Benzinga
Corcept Therapeutics Inc (CORT) Financial Health: Profitability & Balance Sheet Analysis - tradingkey.com
Corcept Therapeutics Inc (CORT) Financial Health: Profitability & Balance Sheet Analysis tradingkey.com
Corcept Therapeutics Inc (CORT) (Q2 2026) Earnings Call Highlights: Record Revenue and ... - Yahoo Finance UK
Corcept Therapeutics Inc (CORT) (Q2 2026) Earnings Call Highlights: Record Revenue and ... Yahoo Finance UK
Corcept Therapeutics (NASDAQ:CORT) Surges 21% After Q2 Earnings Beat and Raised Guidance - ChartMill
Corcept Therapeutics (NASDAQ:CORT) Surges 21% After Q2 Earnings Beat and Raised Guidance ChartMill
Corcept Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingView
Corcept Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary TradingView
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo